Trial Profile
A prospective study of efficacy and safety of atezolizumab for patients with non-small cell lung cancer and interstitial pneumonia
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 18 Nov 2018
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 18 Nov 2018 New trial record